Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung 1

被引：0

作者：

Kilickap, S. ^{[1
]}

Sezer, A. ^{[2
]}

Ozguroglu, M. ^{[3
]}

Gumus, M. ^{[4
]}

Bondarenko, I. ^{[5
]}

Gogishvili, M. ^{[6
]}

Nechaeva, M. ^{[7
]}

Schenker, M. ^{[8
]}

Cicin, I. ^{[1
]}

Fuang, H. G. ^{[9
]}

Kulyaba, Y. ^{[10
]}

Zyuhal, K. ^{[11
]}

Scheusan, R. I. ^{[12
]}

Baramidze, A. ^{[13
]}

Garassino, M. C. ^{[14
]}

Li, Y. ^{[15
]}

Jia, X. ^{[15
]}

Kaul, M. ^{[15
]}

Perez, J. ^{[15
]}

Seebach, F. ^{[15
]}

Lowy, I. ^{[15
]}

Pouliot, J. F. ^{[15
]}

Kim, E. ^{[15
]}

Rietschel, P. ^{[15
]}

Magnan, H. ^{[15
]}

机构：

[1] Istinye Univ, Fac Med, Istanbul, Turkiye

[2] Baskent Univ, Adana, Turkiye

[3] Istanbul Univ Cerrahpasa, Istanbul, Turkiye

[4] Istanbul Medeniyet Univ, Istanbul, Turkiye

[5] Dnipropetrovsk Med Acad, Dnipro, Ukraine

[6] Univ Clin, High Technol Med Ctr, Tbilisi, Georgia

[7] Div Arkhangelsk Clin Oncol Ctr, Arkhangelsk, Russia

[8] Centrul Oncol Sf Nectarie SRL, Craiova, Romania

[9] Univ Malaya, Kuala Lumpur, Malaysia

[10] Prognosis Optima LLC, Kyiv, Ukraine

[11] Multiprofile Hosp Active Treatment, Dobrich, Bulgaria

[12] Oncocenter Oncol Clin, Timisoara, Romania

[13] Todua Clin, Tbilisi, Georgia

[14] Univ Chicago, Knapp Ctr Biomed Discovery, Chicago, IL USA

[15] Regeneron Pharmaceut Inc, Tarrytown, NY USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA11.06

引用

页码：S35 / S35

页数：1

共 50 条

[21] First-line cemiplimab for locally advanced non-small cell lung cancer: Updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3
Kalinka, E.
Bondarenko, I.
Gogishvili, M.
Melkadze, T.
Baramidze, A.
Sezer, A.
Makharadze, T.
Kilickap, S.
Gumus, M.
Penkov, K. D.
Giorgadze, D.
Ozguroglu, M.
He, X.
Pouliot, J-F.
Seebach, F.
Lowy, I.
Gullo, G.
Rietschel, P.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S106 - S106
[22] EMPOWER-lung 1: A randomized, open-label, multi-national, phase III trial of cemiplimab, a human PD-1 monoclonal antibody, versus chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 ≥50%
Sriuranpong, V.
Altundag, O.
Clingan, P.
Rizvi, N.
Frontera, O. Aren
Sezer, A.
Paydas, S.
Shavdia, M.
Bondarenko, I.
Gladkov, O.
Lee, S.
Li, S.
Snodgrass, P.
Rietschel, P.
ANNALS OF ONCOLOGY, 2018, 29
[23] EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
Gogishvili, M.
Melkadze, T.
Makharadze, T.
Giorgadze, D.
Dvorkin, M.
Penkov, K. D.
Laktionov, K.
Nemsadze, G.
Nechaeva, M.
Rozhkova, I.
Kalinka, E.
Gessner, C.
Jaime, B. Moreno
Passalacqua, R.
Li, S.
McGuire, K.
Quek, R. G.
Gullo, G.
Rietschel, P.
ANNALS OF ONCOLOGY, 2022, 33 : S1567 - S1568
[24] Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%
Wang, Liting
Peng, Ye
Zeng, Xiaohui
Peng, Liubao
Li, Sini
Qin, Shuxia
Wan, Xiaomin
Tan, Chongqing
ADVANCES IN THERAPY, 2021, 38 (08) : 4354 - 4365
[25] Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50%
Liting Wang
Ye Peng
Xiaohui Zeng
Liubao Peng
Sini Li
Shuxia Qin
Xiaomin Wan
Chongqing Tan
Advances in Therapy, 2021, 38 : 4354 - 4365
[26] Cemiplimab plus chemotherapy versus chemotherapy in non-small cell lung cancer with PD-L1 ≥1%: EMPOWER-Lung 3 results
Baramidze, A.
Makharadze, T.
Gogishvili, M.
Melkadze, T.
Giorgadze, D.
Penkov, K. D.
Laktionov, K.
Nemsadze, G.
Nechaeva, M.
Rozhkova, I.
Kalinka, E.
McIntyre, D.
Kaul, M.
Quek, R. G. W.
Pouliot, J-F.
Seebach, F.
Gullo, G.
Rietschel, P.
ANNALS OF ONCOLOGY, 2023, 34
[27] EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
Gogishvili, M.
Melkadze, T.
Makharadze, T.
Giorgadze, D.
Dvorkin, M.
Penkov, K. D.
Laktionov, K.
Nemsadze, G.
Nechaeva, M.
Rozhkova, I.
Kalinka, E.
Gessner, C.
Moreno-Jaime, B.
Passalacqua, R.
Li, S.
McGuire, K.
Quek, R. G. W.
Gullo, G.
Rietschel, P.
ANNALS OF ONCOLOGY, 2021, 32 : S1328 - S1328
[28] Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation
Bondarenko, I.
Sezer, A.
Kilickap, S.
Gumus, M.
Ozguroglu, M.
Gogishvili, M.
He, X.
Gullo, G.
Rietschel, P.
Quek, R. G.
ANNALS OF ONCOLOGY, 2022, 33 : S84 - S85
[29] PD-L1 Very High Expression Associated with Clinical Outcome of Pembrolizumab Monotherapy of Advanced NSCLC with PD-L1 TPS of 50% or Greater
Itani, H.
Nigi, A.
Iwamoto, K.
Ito, Y.
Tanigawa, M.
Kondo, S.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S662 - S663
[30] First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a multicentre, open-label, randomised, phase 3 trial
Ozguroglu, Mustafa
Kilickap, Saadettin
Sezer, Ahmet
Gumus, Mahmut
Bondarenko, Igor
Gogishvili, Miranda
Nechaeva, Marina
Schenker, Michael
Cicin, Irfan
Ho, Gwo Fuang
Kulyaba, Yaroslav
Zyuhal, Kasimova
Scheusan, Roxana-Ioana
Garassino, Marina Chiara
He, Xuanyao
Kaul, Manika
Okoye, Emmanuel
Li, Yuntong
Li, Siyu
Pouliot, Jean-Francois
Seebach, Frank
Lowy, Israel
Gullo, Giuseppe
Rietschel, Petra
LANCET ONCOLOGY, 2023, 24 (09): : 989 - 1001

← 1 2 3 4 5 →